Genentech Biooncology
Genentech Biooncology
    • Home 

    • Pipeline Molecules 

    • Onartuzumab (MetMAb) 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
    • Overview
    • Akt Inhibitor (GDC-0068)
    • Anti-CD22 ADC (DCDT2980S)
    • Anti-CD79b ADC (DCDS4501A)
    • Anti-HER3/EGFR MAb (MEHD7945A)
    • Anti-PDL1 (MPDL3280A)
    • Bcl-2-Specific Inhibitor (GDC-0199)
    • MEK Inhibitor (GDC-0973)
    • Onartuzumab (MetMAb)
    • Parsatuzumab (Anti-EGFL7)
    • PI3K Inhibitor (GDC-0941)
    • PI3K/mTOR Inhibitor (GDC-0980)
  • Research Education
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Tumor Types
    • Colorectal Cancer
    • Lung Cancer
  • Clinical Trials
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
  • Cancer Biomarkers
    • Breast Cancer
      • Receptor-Mediated Endocytosis
      • Genome instability and mutation
      • Cytotoxic agent
      • What are ADCs?
      • Stable linker
      • Monoclonal antibody
      • Current research in ADCs
      • Targeting cancers with ADCs
      • Glossary
      • A brief history of ADCs
      • How are ADCs designed to work?
      • Research ADCs
      • Multimedia Resources
      • HER2+ breast cancer
      • HER2 dimerization
      • Research HDIs
      • Slide decks and videos
      • HER2:HER3 dimer
      • Glossary
      • HER1/EGFR evaluation
      • HER1/EGFR in lung cancer
      • HER1/EGFR in pancreatic cancer
      • HER1/EGFR and prognosis
      • Summary
      • HER1/EGFR as a therapeutic target
      • HER2 in breast cancer
      • HER2 detection methods
      • HER2 dysregulation
      • HER2
      • HER2 in ovarian cancer
      • HER2 and prognosis
      • Summary
      • HER2 as a therapeutic target
      • HER3 in breast cancer
      • HER3 dysregulation
      • HER3 evaluation
      • HER3
      • HER3 in ovarian cancer
      • Summary
      • HER3 as a therapeutic target
      • HER4
      • HER pathways slide decks and videos
      • Receptor activation
      • Cancer effects
      • Dimerization
      • Overview
      • HER ligands
      • HER receptors
      • Summary
      • Therapeutic potential of HER pathways
      • Research MET
      • What is Met?
      • Breast Cancer
    • Colorectal Cancer
      • Oncogenic BRAF and prognosis
      • Oncogenic BRAF in cancer
      • VEGF in colorectal cancer
      • Adjuvant fluoropyrimidines
      • VEGF as a predictive factor
      • Preoperative radiotherapy
      • VEGF and prognosis
      • Metastasis
      • Increased risk of relapse
      • Survival
      • Tumor invasion/lymph node involvement
      • Summary
      • Evidence of VEGF expression
    • Lung Cancer
      • Receptor-Mediated Endocytosis
      • Cytotoxic agent
      • What are ADCs?
      • Stable linker
      • Monoclonal antibody
      • Current research in ADCs
      • Targeting cancers with ADCs
      • Glossary
      • A brief history of ADCs
      • How are ADCs designed to work?
      • Research ADCs
      • Multimedia Resources
      • VEGF in lung cancer
      • Prevalence of VEGF
      • VEGF and prognosis
      • Malignant pleural effusion
      • Survival
      • Summary
      • Evidence of VEGF expression
      • VEGF and disease progression
  • Future Directions
    • Antibody-Drug conjugates
      • HER Signaling
      • Receptor-Mediated Endocytosis
      • Anti-HER3/EGFR MAb (MEHD7945A)
      • Anti-PDL1 (MPDL3280A)
      • Cytotoxic agent
      • What are ADCs?
      • Stable linker
      • Monoclonal antibody
      • Current research in ADCs
      • Targeting cancers with ADCs
      • Glossary
      • A brief history of ADCs
      • How are ADCs designed to work?
      • Research ADCs
      • Multimedia Resources
      • Emerging therapeutic options
      • Emerging therapeutic options
      • HER2:HER3 dimer
      • Glossary
      • HER1/EGFR evaluation
      • HER1/EGFR in lung cancer
      • HER1/EGFR in pancreatic cancer
      • HER1/EGFR and prognosis
      • Summary
      • HER1/EGFR as a therapeutic target
      • HER2 in breast cancer
      • HER2 detection methods
      • HER2 dysregulation
      • HER2
      • HER2 in ovarian cancer
      • HER2 and prognosis
      • Summary
      • HER2 as a therapeutic target
      • HER3 in breast cancer
      • HER3 dysregulation
      • HER3 evaluation
      • HER3
      • HER3 in ovarian cancer
      • Summary
      • HER3 as a therapeutic target
      • HER4
      • HER pathways slide decks and videos
      • Receptor activation
      • Cancer effects
      • Dimerization
      • Overview
      • HER ligands
      • HER receptors
      • Summary
      • Therapeutic potential of HER pathways
      • Research MET
      • What is Met?
    • Apoptosis
      • Emerging therapeutic options
    • Bispecific Monoclonal Antibodies
      • Emerging therapeutic options
      • Emerging therapeutic options
      • Emerging therapeutic options
    • Glycoengineered Antibodies
      • HER Signaling
      • Anti-HER3/EGFR MAb (MEHD7945A)
      • Emerging therapeutic options
      • Emerging therapeutic options
      • Emerging therapeutic options
    • Non-Antibody Biologics
      • Apoptosis
      • Extrinsic pathway
      • What are the strategies for inhibiting the VEGF pathway?
    • Targeted Small Molecules
      • Apoptosis
      • MAPK Signaling
      • PI3K/Akt/mTOR Signaling
      • Anti-HER3/EGFR MAb (MEHD7945A)
      • MEK Inhibitor (GDC-0973)
      • PI3K Inhibitor (GDC-0941)
      • Glossary
      • Apoptosis
      • The Bcl-2 family
      • Apoptotic pathways
      • Reactivating apoptosis
      • Resisting apoptosis
      • Useful resources
      • Emerging therapeutic options
      • Emerging therapeutic options
      • Emerging therapeutic options
      • HER2:HER3 dimer
      • Glossary
      • HER1/EGFR evaluation
      • HER1/EGFR in lung cancer
      • HER1/EGFR in pancreatic cancer
      • HER1/EGFR and prognosis
      • Summary
      • HER1/EGFR as a therapeutic target
      • HER2 in breast cancer
      • HER2 detection methods
      • HER2 dysregulation
      • HER2
      • HER2 in ovarian cancer
      • HER2 and prognosis
      • Summary
      • HER2 as a therapeutic target
      • HER3 in breast cancer
      • HER3 dysregulation
      • HER3 evaluation
      • HER3
      • HER3 in ovarian cancer
      • Summary
      • HER3 as a therapeutic target
      • HER4
      • HER pathways slide decks and videos
      • Receptor activation
      • Cancer effects
      • Dimerization
      • Overview
      • HER ligands
      • HER receptors
      • Summary
      • Therapeutic potential of HER pathways
      • Research MET
      • What is Met?
      • Slide decks and videos
      • What are the strategies for inhibiting the VEGF pathway?
      • Gastric Cancer
      • Melanoma
    • Traditional Monoclonal Antibodies
      • Angiogenic Signaling
      • B-cell Surface Proteins
      • HER Signaling
      • Parsatuzumab (Anti-EGFL7)
      • Anti-HER3/EGFR MAb (MEHD7945A)
      • Anti-PDL1 (MPDL3280A)
      • Direct cell death
      • Emerging therapeutic options
      • Emerging therapeutic options
      • Emerging therapeutic options
      • Inhibition of HER2 dimerization
      • HER2:HER3 dimer
      • Glossary
      • HER1/EGFR evaluation
      • HER1/EGFR in lung cancer
      • HER1/EGFR in pancreatic cancer
      • HER1/EGFR and prognosis
      • Summary
      • HER1/EGFR as a therapeutic target
      • HER2 in breast cancer
      • HER2 detection methods
      • HER2 dysregulation
      • HER2
      • HER2 in ovarian cancer
      • HER2 and prognosis
      • Summary
      • HER2 as a therapeutic target
      • HER3 in breast cancer
      • HER3 dysregulation
      • HER3 evaluation
      • HER3
      • HER3 in ovarian cancer
      • Summary
      • HER3 as a therapeutic target
      • HER4
      • HER pathways slide decks and videos
      • Receptor activation
      • Cancer effects
      • Dimerization
      • Overview
      • HER ligands
      • HER receptors
      • Summary
      • Therapeutic potential of HER pathways
      • Research MET
      • What is Met?
      • Glossary
      • Slide decks and videos
      • What are the strategies for inhibiting the VEGF pathway?
      • Gastric Cancer
      • Melanoma
Share

MetMAb

Blocking HGF/SF binding may prevent Met dimerization and activation, ultimately inhibiting downstream signaling events.1,2

GA101
Click here to view a larger version of this image

Onartuzumab (MetMAb) is a monovalent (one-armed), monoclonal antibody designed to bind to Met and inhibit HGF/SF binding.3,4 Traditional bivalent antibodies to Met potentially activate, rather than inhibit, Met signaling by inducing Met dimerization.5-6 In contrast, the monovalent design of Onartuzumab (MetMAb) inhibits HGF/SF binding without inducing Met dimerization.4 Onartuzumab (MetMAb) has demonstrated antitumor activity in preclinical analyses.4

  1. MetMAb was specifically designed as a monovalent antibody to avoid agonistic activity that may occur when a bivalent antibody binds two Met molecules.4,6

    MetMAb Vignette 1

  2. MetMAb binds to the Sema domain of Met, an extracellular region essential for binding its ligand, HGF/SF.3,4

    MetMAb Vignette 2

  3. MetMAb inhibits HGF/SF from binding to Met, thereby blocking ligand-induced Met dimerization and activation of the intracellular kinase domain.4

    MetMAb Vignette 3

  4. Blockade of Met activation inhibits its downstream pathways, preventing cancer cell growth, survival, and metastasis.4

    MetMAb Vignette 4

References:
1.
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915-925. PMID: 14685170
2.
Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol. 2005;7:436-451. PMID: 16212809
3.
Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell. 2004;6:75-84. PMID: 15261143
4.
Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 2006;12:6144-6152. PMID: 17062691
5.
Ohashi K, Marion PL, Nakai H, et al. Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses. Nat Med. 2000;6:327-331. PMID: 10700236
6.
Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci. 1998;111:237-247. PMID: 9405310
 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0001755100
Next section: Parsatuzumab (Anti-EGFL7) »

© 2011 Genentech USA, Inc. All rights reserved